Fresenius Kabi has successfully closed the acquisition of Merck KGaA’s biosimilars business. The transaction comprises the entire development pipeline of Merck’s biosimilars and an experienced team of employees located in Aubonne and Vevey, Switzerland. The product pipeline has a focus on oncology and autoimmune diseases, and addresses a market with current annual branded sales of around US$30bn. The biosimilars business will be consolidated as of September 1, 2017.
The purchase price of €656 million will be mainly cash flow financed. Thereof, €156 million have been paid upon closing. Up to €500 million are milestone payments strictly tied to achievements of development targets in the coming years. The slight reduction in purchase price is related to phasing of R&D expenditures between signing and closing of the acquisition. These are now expected to amount to around €60 million from closing until year-end 2017. All clinical studies for the product pipeline are on track.
The transaction is estimated to be EBITDA break-even in 2022. From 2023 onwards, the acquisition is expected to be significantly accretive to Group net income1 and Group EPS1.
The relevant antitrust authorities have approved the transaction without imposing conditions.
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius Kabi has successfully closed the acquisition of Merck KGaA’s biosimilars business. The transaction comprises the entire development pipeline of Merck’s biosimilars and an experienced team of employees located in Aubonne and Vevey, Switzerland. The product pipeline has a focus on oncology and autoimmune diseases, and addresses a market with current annual branded sales of around US$30bn. The biosimilars business will be consolidated as of September 1, 2017.
The purchase price of €656 million will be mainly cash flow financed. Thereof, €156 million have been paid upon closing. Up to €500 million are milestone payments strictly tied to achievements of development targets in the coming years. The slight reduction in purchase price is related to phasing of R&D expenditures between signing and closing of the acquisition. These are now expected to amount to around €60 million from closing until year-end 2017. All clinical studies for the product pipeline are on track.
The transaction is estimated to be EBITDA break-even in 2022. From 2023 onwards, the acquisition is expected to be significantly accretive to Group net income and Group EPS1.
The relevant antitrust authorities have approved the transaction without imposing conditions.
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
The amended 2013 Credit Agreement streamlines Fresenius’ financing structure by replacing the existing senior secured facilities with unsecured facilities. Concurrently, the guarantor structure was aligned, with Fresenius SE & Co KGaA now being sole guarantor. The Credit Agreement has an aggregate amount of approximately €3.8 billion and consists of revolving facilities and term loans with maturities in 2021 and 2022. The transaction was well received by investors and substantially oversubscribed. On the basis of the unsecured structure and consistent with the corporate credit rating of Fresenius, S&P has raised the rating of the Fresenius bonds to BBB- from BB+.
The amended 2013 Credit Agreement streamlines Fresenius’ financing structure by replacing the existing senior secured facilities with unsecured facilities. Concurrently, the guarantor structure was aligned, with Fresenius SE & Co KGaA now being sole guarantor. The Credit Agreement has an aggregate amount of approximately €3.8 billion and consists of revolving facilities and term loans with maturities in 2021 and 2022. The transaction was well received by investors and substantially oversubscribed. On the basis of the unsecured structure and consistent with the corporate credit rating of Fresenius, S&P has raised the rating of the Fresenius bonds to BBB- from BB+.
Fresenius Helios continues to invest in the expansion and modernization of its hospitals and clinics. HELIOS Clinic Geesthacht, located just east of Hamburg, has opened an extension with 20 additional neurological rehabilitation places for young people. The investment in the specialist clinic for neurology and neurological rehabilitation is €4.6 million. In the state of Saxony, meanwhile, work has started on a new building for the emergency ward at HELIOS Hospital Leisnig. This €3.3 million project is scheduled for completion in autumn 2018.
Fresenius Helios continues to invest in the expansion and modernization of its hospitals and clinics. HELIOS Clinic Geesthacht, located just east of Hamburg, has opened an extension with 20 additional neurological rehabilitation places for young people. The investment in the specialist clinic for neurology and neurological rehabilitation is €4.6 million. In the state of Saxony, meanwhile, work has started on a new building for the emergency ward at HELIOS Hospital Leisnig. This €3.3 million project is scheduled for completion in autumn 2018.